Abstract:BackgroundAlzheimer's disease (AD) is a fatal disease that threatens the quality of life of an aging population at a global scale. Various hypotheses on the etiology of AD have been developed over the years to guide efforts in search of therapeutic strategies.Main bodyIn this review, we focus on four AD hypotheses currently relevant to AD onset: the prevailing amyloid cascade hypothesis, the well-recognized tau hypothesis, the increasingly popular pathogen (viral infection) hypothesis, and the infection-related antimicrobial protection hypothesis. In briefly reviewing the main evidence supporting each hypothesis and discussing the questions that need to be addressed, we hope to gain a better understanding of the complicated multi-layered interactions in potential causal and/or risk factors in AD pathogenesis. As a defining feature of AD, the existence of amyloid deposits is likely fundamental to AD onset but is insufficient to wholly reproduce many complexities of the disorder. A similar belief is currently also applied to hyperphosphorylated tau aggregates within neurons, where tau has been postulated to drive neurodegeneration in the presence of pre-existing A plaques in the brain. Although infection of the central nerve system by pathogens such as viruses may increase AD risk, it is yet to be determined whether this phenomenon is applicable to all cases of sporadic AD and whether it is a primary trigger for AD onset. Lastly, the antimicrobial protection hypothesis provides insight into a potential physiological role for A peptides, but how A/microbial interactions affect AD pathogenesis during aging awaits further validation. Nevertheless, this hypothesis cautions potential adverse effects in A-targeting therapies by hindering potential roles for A in anti-viral protection.ConclusionAD is a multi-factor complex disorder, which likely requires a combinatorial therapeutic approach to successfully slow or reduce symptomatic memory decline. A better understanding of how various causal and/or risk factors affecting disease onset and progression will enhance the likelihood of conceiving effective treatment paradigms, which may involve personalized treatment strategies for individual patients at varying stages of disease progression.

Pathogenesis and Therapeutic Strategies in Alzheimer’s Disease: from Brain to Periphery

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

Progress in pathogenesis and treatment of Alzheimer's disease

New Insights Into the Pathogenesis of Alzheimer's Disease

Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease

Pathogenesis of Alzheimer's disease and therapeutic strategies involving traditional Chinese medicine

Pathogen Infection in Alzheimer’s Disease: Pathophysiology and Therapeutic Strategies

Alzheimer's disease: insights into pathology, molecular mechanisms, and therapy.

Research Progress on the Pathogenesis, Diagnosis, and Drug Therapy of Alzheimer's Disease

Pathological mechanisms and therapeutic strategies for Alzheimer’s disease

Prevention and Treatment Strategies for Alzheimer's Disease: Focusing on Microglia and Astrocytes in Neuroinflammation

Microglia in the Neuroinflammatory Pathogenesis of Alzheimer's Disease and Related Therapeutic Targets

Recent trends in treatment strategies for Alzheimer's disease and the challenges: A topical advancement

Exploring the Therapeutic Potential of Natural Compounds for Alzheimer's Disease: Mechanisms of Action and Pharmacological Properties.

Amyloid, Tau, Pathogen Infection and Antimicrobial Protection in Alzheimer’s Disease –conformist, Nonconformist, and Realistic Prospects for AD Pathogenesis

Neuroinflammation of Microglial Regulation in Alzheimer's Disease: Therapeutic Approaches

Alzheimer Disease Pathogenesis: Insights From Molecular and Cellular Biology Studies of Oligomeric Aβ and Tau Species

Novel Disease-Modifying Therapies for Alzheimer's Disease.

Pathogenesis, Animal Models, and Drug Discovery of Alzheimer’s Disease

The Amyloid-Beta Clearance: From Molecular Targets to Glial and Neural Cells

Regulation of beta‐amyloid for the treatment of Alzheimer's disease: Research progress of therapeutic strategies and bioactive compounds